# AstraZeneca’s Klygefa recommended for EU approval in generalised myasthenia gravis

- Link: https://www.directorstalkinterviews.com/astrazeneca-s-klygefa-recommended-for-eu-approval-in-generalised-myasthenia-gravis/4121263136
- Published: 2026-09-21T07:08:00+01:00
- Author: Amilia Stone

Alexion,** [AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
Rare Disease’s _Klygefa_ (gefurulimab) has been recommended for approval in the 
European Union (EU) as an add-on to standard therapy for the treatment of generalised
myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-
positive. If approved, _Klygefa_ will be the first and only dual-binding nanobody
C5 inhibitor for this patient population. 

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines
Agency (EMA) based its positive opinion on results from the pivotal PREVAIL Phase
III trial, which were presented at the Myasthenia Gravis Foundation of America (
MGFA) Scientific Session during the American Association of Neuromuscular & Electrodiagnostic
Medicine (AANEM) 2025 Annual Meeting and published in JAMA Neurology.^(1)

gMG is a rare autoimmune disorder characterised by reduced muscle function and severe
muscle weakness.^(2) An estimated 82,500 people are diagnosed with gMG in Europe
5 countries (Germany, France, UK, Italy and Spain) with 66,000 being AChR-positive.
^(3)

> **Tobias Ruck, MD, Director Department of Neurology, BG University Hospital Bergmannsheil
> Bochum, Ruhr-University Bochum and investigator in the trial, said**: “For people
> living with gMG, unpredictable symptoms can quickly become incapacitating or life-
> threatening. In the PREVAIL Phase III trial, gefurulimab demonstrated the ability
> to improve measures of disease severity and daily function with the convenience
> of once weekly subcutaneous self-administration, as early as one week and through
> the 26-week study period. With this positive CHMP opinion patients may soon have
> the option of a novel treatment option that could help them spend less time thinking
> about their care and more time living their lives.”

> **Marc Dunoyer, Chief Executive Officer, Alexion, said**: “This positive CHMP 
> opinion is an important step towards bringing _Klygefa_, an innovative dual-binding
> nanobody C5 inhibitor, to people living with gMG in the EU. Building on our pioneering
> work demonstrating the efficacy of C5 inhibition with _Soliris_ and _Ultomiris_,
> _Klygefa_ is designed to offer rapid and sustained symptom control with convenient
> once-weekly subcutaneous self-administration via autoinjector.”

Results from the PREVAIL trial showed that _Klygefa_ met its primary endpoint, demonstrating
improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL)
total score at week 26 compared to placebo (treatment difference: -1.6 [95% CI: -
2.4, -0.8], p<0.0001). A clinically meaningful improvement was observed as early
as week one, and was sustained through week 26.^(1)

_Klygefa_ was generally well-tolerated, and the safety profile was consistent with
previous trials of C5 inhibitors eculizumab and ravulizumab in gMG.^(1)

_Klygefa_ is approved in Japan and other countries for certain adults with gMG. 
Regulatory submissions based on the PREVAIL results are under review in the US, 
China and additional countries.

**References**

1.   Gwathmey KG, Saccà F, Howard JF Jr, et al. Efficacy and safety of gefurulimab
in generalized myasthenia gravis: the PREVAIL phase 3 randomized clinical trial.
_JAMA Neurol._ 2026 Jul 27.

2.    Jung-Plath W, et al. Assessment of myasthenia gravis patients’ quality of 
life. _The Journal of Neurosurgical Nursing_. 2023;12(2):74-83.

3.    AstraZeneca Data on File – Epidemiology estimates are composed of a triangulation
of different data sources including Data Monitor, Decision Resources Group, Kantar
Health, and internal input. Accessed September 2026.

Share on:
